Publication | Closed Access

HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial

ObesityMetabolic SyndromeHepatologyObese SubjectsMedicineLiver PhysiologyPhysiologyDiabetesObesity ManagementLiver FatPhase 1B/2aLiver DiseaseFatty Liver DiseaseMetabolismPharmacologyHealth Sciences